UK markets close in 6 hours 24 minutes
  • FTSE 100

    7,118.51
    +35.14 (+0.50%)
     
  • FTSE 250

    23,909.36
    +124.82 (+0.52%)
     
  • AIM

    1,274.71
    +6.58 (+0.52%)
     
  • GBP/EUR

    1.1652
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.3663
    +0.0044 (+0.32%)
     
  • BTC-GBP

    32,134.66
    +1,055.02 (+3.39%)
     
  • CMC Crypto 200

    1,103.86
    +63.38 (+6.09%)
     
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • DOW

    34,258.32
    +338.48 (+1.00%)
     
  • CRUDE OIL

    72.27
    +0.04 (+0.06%)
     
  • GOLD FUTURES

    1,769.30
    -9.50 (-0.53%)
     
  • NIKKEI 225

    29,639.40
    -200.31 (-0.67%)
     
  • HANG SENG

    24,510.98
    +289.44 (+1.19%)
     
  • DAX

    15,661.13
    +154.39 (+1.00%)
     
  • CAC 40

    6,705.17
    +68.17 (+1.03%)
     

Axonics® Reports Second Quarter 2021 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·8-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Total revenue of $45.9 million in 2Q21, including record SNM revenue of $40.2 million

Bulkamid® revenue of $5.7 million in first full quarter since acquisition

Fiscal year 2021 revenue guidance increased to a range of $186 million to $188 million

IRVINE, Calif., August 05, 2021--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the second quarter ended June 30, 2021.

"This quarter’s record revenue result reflects the growing demand for our best-in-class incontinence solutions," said Raymond W. Cohen, chief executive officer of Axonics. "Clinical outcomes and satisfaction with our rechargeable sacral neuromodulation (SNM) system remain high, with over 12,000 patients having been implanted since our U.S. commercial launch in late 2019. Given the strong commercial momentum for both SNM and Bulkamid, we have increased our fiscal year 2021 revenue guidance to be in the range of $186 million to $188 million."

Cohen continued, "During the second quarter, we trained our entire U.S. field team on Bulkamid and are now executing a broad rollout to physicians across the United States. Physician enthusiasm to incorporate this next-generation bulking agent into their practices to treat female stress urinary incontinence is significant as evidenced by our second quarter results and the six fully booked regional seminars we are hosting this summer to provide Bulkamid wet-lab training. In late June, we filed a PMA supplement with the FDA for our new long-lived, non-rechargeable implantable neurostimulator. We anticipate the 10-year life and fully recharge-free system will be a very attractive proposition for patients and physicians. The progress on these key initiatives and the continued expansion of our U.S. commercial team gives us confidence in achieving our ambitious long-term growth objectives."

Second Quarter 2021 Financial Results

  • Net revenue was $45.9 million in the second quarter 2021, an increase of 202% compared to $15.2 million in the prior year period.

    • Sacral neuromodulation revenue was $40.2 million, of which $39.2 million was generated in the U.S. and the remainder in select international markets.

    • Bulkamid revenue was $5.7 million, of which $2.4 million was generated in the U.S. and the remainder in international markets.

  • Gross margin was 62.6% in the second quarter 2021 compared to 44.4% in the prior year period.

  • Operating expenses were $44.7 million in the second quarter 2021 compared to $26.2 million in the prior year period.

  • Net loss was $25.1 million in the second quarter 2021 compared to a net loss of $19.8 million in the prior year period.

  • As of June 30, 2021, cash and cash equivalents were $231.1 million. In mid-June, Axonics prepaid and terminated its $75 million term loan with Silicon Valley Bank.

Second Quarter 2021 Corporate Highlights

  • On May 14, 2021, Axonics completed a public stock offering of 4,025,000 shares at $50 per share, generating gross proceeds of $201.3 million.

  • On May 18, 2021, Axonics announced CE Mark approval for its second generation rechargeable INS and wireless patient remote control with SmartMRI™ technology.

  • On May 20, 2021, Axonics announced FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI scans.

  • On June 24, 2021, Axonics announced the filing of a PMA supplement with the FDA for its non-rechargeable INS.

Fiscal Year 2021 Revenue Guidance

Axonics is increasing its fiscal year 2021 revenue guidance as follows:

  • Total net revenue to be in the range of $186 million to $188 million, representing growth of approximately 67% to 69% over fiscal year 2020 net revenue of $111.5 million. This compares to the prior net revenue outlook of $176 million to $180 million.

  • Sacral neuromodulation (SNM) net revenue to be in the range of $166 million to $168 million.

  • Bulkamid net revenue of $20 million.

Webcast and Conference Call

Axonics will host a conference call today, August 5, 2021, at 4:30 p.m. Eastern Time, to discuss financial results and recent business developments. The live teleconference may be accessed by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 3072186.

A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Axonics website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid®, provides women suffering from stress urinary incontinence (SUI) with safe and durable symptom relief.

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Forward-Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as "planned," "expects," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Axonics, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(in thousands, except share and per share data)

(unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2021

2020

2021

2020

Sacral neuromodulation net revenue

$

40,194

$

15,213

$

73,097

$

41,509

Bulkamid net revenue

5,675

7,145

Total net revenue

45,869

15,213

80,242

41,509

Cost of goods sold

17,135

8,463

31,109

18,358

Gross profit

28,734

6,750

49,133

23,151

Operating Expenses

Research and development

9,098

6,370

18,467

13,225

General and administrative

8,035

5,537

14,661

13,190

Sales and marketing

25,411

14,220

46,339

30,789

Amortization of intangible assets

2,200

28

2,878

57

Acquisition-related costs

4,414

Total operating expenses

44,744

26,155

86,759

57,261

Loss from operations

(16,010

)

(19,405

)

(37,626

)

(34,110

)

Other Income (Expense)

Interest income

7

65

15

707

Interest and other expense

(5,849

)

(443

)

(7,299

)

(995

)

Other expense, net

(5,842

)

(378

)

(7,284

)

(288

)

Loss before income tax expense

(21,852

)

(19,783

)

(44,910

)

(34,398

)

Income tax expense

3,296

2,741

1

Net loss

(25,148

)

(19,783

)

(47,651

)

(34,399

)

Foreign currency translation adjustment

859

(108

)

(1,343

)

(285

)

Comprehensive loss

$

(24,289

)

$

(19,891

)

$

(48,994

)

$

(34,684

)

Net loss per share, basic and diluted

$

(0.59

)

$

(0.54

)

$

(1.16

)

$

(0.98

)

Weighted-average shares used to compute basic and diluted net loss per share

42,788,678

36,440,846

41,210,091

35,040,180

Axonics, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

June 30,

December 31,

2021

2020

(unaudited)

ASSETS

Current assets

Cash and cash equivalents

$

231,140

$

241,181

Accounts receivable, net of allowance for doubtful accounts of $385 and $465 at June 30, 2021 and December 31, 2020, respectively

25,646

18,270

Inventory, net

70,391

63,060

Prepaid expenses and other current assets

5,006

5,435

Total current assets

332,183

327,946

Property and equipment, net

5,958

6,328

Intangible assets, net

113,416

196

Other assets

7,324

7,736

Goodwill

106,631

Total assets

$

565,512

$

342,206

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

Accounts payable

$

9,447

$

10,660

Accrued liabilities

6,305

6,684

Accrued compensation and benefits

7,198

5,948

Operating lease liability, current portion

1,407

1,280

Debt, net of unamortized debt issuance costs, current portion

30

21,110

Total current liabilities

24,387

45,682

Operating lease liability, net of current portion

8,481

9,154

Debt, net of unamortized debt issuance costs, net of current portion

89

Deferred tax liabilities, net

20,626

Other long-term liabilities

7,664

Total liabilities

61,247

54,836

Stockholders’ equity

Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2021 and December 31, 2020

Common stock, par value $0.0001, 50,000,000 shares authorized at June 30, 2021 and December 31, 2020; 46,090,964 and 39,931,030 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively

5

4

Additional paid-in capital

788,184

522,296

Accumulated deficit

(282,150

)

(234,499

)

Accumulated other comprehensive loss

(1,774

)

(431

)

Total stockholders’ equity

504,265

287,370

Total liabilities and stockholders’ equity

$

565,512

$

342,206

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005888/en/

Contacts

Axonics contact:
Neil Bhalodkar
Investor Relations
949-336-5293
IR@axonics.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting